IT - EN
Pharmaceutical Operations

Pharmaceutical OperationsR & DPipeline

NAME ORIGINATOR INDICATION DEVELOPMENT STATUS
ISTURISA® Novartis Endogenous Cushing's syndrome/
Cushing's diseases                                                  
Approved in Europa
Approved in the USA
CYSTADROPS® Recordati  Corneal cysteine crystal deposits in patients with cystinosis Filed in the USA
Development of new formulations in EU and in USA
REAGILA® Gedeon Richter Schizophrenia Pediatric post-approval development plan
metadone   Treatment of cancer-related pain in cases of resistance or intolerance to other opioids Approved in France
CARBAGLU® Orphan Europe  (Recordati) Hyperammonaemia due to NAGS deficiency and to the main organic acidemias Development of new formulations in EU and USA
Filed in the USA for the organic acidemias indication
REC 0438 Recordati/UFPeptides New indications Preclinical development
REC 0559 Recordati/Mime Tech Neurotrophic keratitis Formulation development
Clinical development planning
REC 0545 Recordati/AP-HP Acute decompensation episodes in MSUD Formulation development
Retrospective study in France and Germany